Avidity Biosciences. has filed a patent for polynucleic acid molecules aimed at treating muscle dystrophy (DM1). The patent includes specific sequences and modifications for targeting DMPK mRNA. GlobalData’s report on Avidity Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Avidity Biosciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Avidity Biosciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Avidity Biosciences's grant share as of January 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of muscle dystrophy using polynucleic acid molecules

Source: United States Patent and Trademark Office (USPTO). Credit: Avidity Biosciences Inc

A recently filed patent (Publication Number: US20230398231A1) discloses a polynucleic acid molecule designed to target a specific sequence of DMPK mRNA. The molecule consists of a sense strand with a nucleic acid sequence of SEQ ID NO: 1 and an antisense strand with a nucleic acid sequence of SEQ ID NO: 2. Notably, the antisense strand incorporates 2'-F modified nucleotides at specific positions from the 5'-end, enhancing its efficacy in targeting the mRNA transcript.

Furthermore, the patent claims a polynucleic acid molecule conjugate that includes an anti-transferrin receptor antibody or its antigen binding fragment linked to the polynucleic acid molecule. This conjugate aims to target the DMPK mRNA transcript effectively. The patent also outlines a method for treating muscular dystrophy using the disclosed polynucleic acid molecule or its conjugate, which works by reducing the quantity of the mRNA transcript of human DMPK. This innovative approach holds promise for potential therapeutic interventions in individuals with muscular dystrophy, showcasing the application of advanced nucleic acid technology in addressing genetic disorders.

To know more about GlobalData’s detailed insights on Avidity Biosciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies